Market Cap : 118.9 M | Enterprise Value : 81.71 M | PE Ratio : At Loss | PB Ratio : 1.70 |
---|
NAS:STIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:STIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neuronetics's enterprise value is $81.71 Mil. Neuronetics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-35.15 Mil. Therefore, Neuronetics's EV-to-EBITDA for today is -2.32.
The historical rank and industry rank for Neuronetics's EV-to-EBITDA or its related term are showing as below:
During the past 6 years, the highest EV-to-EBITDA of Neuronetics was 0.01. The lowest was -29.74. And the median was -4.05.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-11), Neuronetics's stock price is $4.40. Neuronetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.400. Therefore, Neuronetics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Neuronetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Neuronetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neuronetics's EV-to-EBITDA falls into.
Neuronetics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 81.710 | / | -35.147 | |
= | -2.32 |
Neuronetics's current Enterprise Value is $81.71 Mil.
Neuronetics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Neuronetics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 4.40 | / | -1.400 | |
= | At Loss |
Neuronetics's share price for today is $4.40.
Neuronetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Neuronetics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cannell Capital Llc | 10 percent owner | 245 MERIWETHER CIRCLE ALTA WY 83414 |
Rosengarten Megan | director | C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 |
Cascella Robert | director | C/O HOLOGIC, INC. BEDFORD MA 01730 |
Shook Bruce Joseph | director | 162 CRICKET AVE ARDMORE PA 19003 |
Jaeger Wilfred E | director | C/O THREE ARCH PARTNERS 3200 ALPINE RD PORTOLA VALLEY CA 94028 |
Bakewell John K | director | C/O LANTHEUS MEDICAL IMAGING, INC. 331 TREBLE COVE ROAD NO. BILLERICA MA 01862 |
Conley Sheryl L | director | C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 |
Muir Glenn P | director | C/O HOLOGIC, INC. BEDFORD MA 01730 |
Sullivan Keith J | director, officer: President and CEO | C/O RELIANT TECHNOLOGIES, INC. 464 ELLIS STREET MOUNTAIN VIEW CA 94043 |
Macan William Andrew | officer: Sr. VP, GC, CCO and Secretary | 24275 KATY FREEWAY, SUITE 600 KATY TX 77494 |
Harper Gregory | officer: VP of Prod. Dev. & Operations | C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355 |
Furlong Stephen | officer: CFO | C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 |
Tropsha Yelena | officer: VP of Commercial Access | C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355 |
Farley Brian E | director | 2200 ZANKER ROAD SUITE F SAN JOSE CA 95131 |
Guthrie Daniel | officer: Chief Commercial Officer | C/O NEURONETICS, INC 322 PHOENIXVILLE PIKE MALVERN PA 19355 |
From GuruFocus
Other Sources
By Zacks 2022-03-09
By Seekingalpha 2020-11-03
By Seekingalpha 2021-03-02
By Zacks 2021-03-02
By Zacks 2022-03-10
By Zacks 2020-08-04
By Zacks 2022-02-24
By Zacks 2022-03-08
By Seekingalpha 2021-11-09
By Zacks 2021-08-31